Zika Virus in the Americas: An HHS Expert Consultation to Accelerate the Development of Countermeasures

Anthony S. Fauci, M.D.
Director
National Institute of Allergy and Infectious Diseases
March 28, 2016

Advancing Countermeasures for Zika Virus

Vital Research and Development Partnerships

Product Development Pipeline

Early concept and product development | Advanced development | Commercial manufacturing | Regulatory review
NIH | BARDA | Industry | FDA

Product Development Pipeline for Zika

Early concept and product development
NIH
BARDA
Industry
FDA consultation and interim review

Goals of the Consultation:
- Review the current information about the epidemiology and natural history (including potential link to microcephaly and other fetal malformations), clinical manifestations, modes of transmission and pathogenesis of Zika virus.
- Identify critical gaps in knowledge, technologies, research infrastructure and regulatory oversight needed to address the current epidemic.
- Discuss strategies to accelerate the development of vaccines, diagnostics, therapeutics and novel vector control methods.
Key Issues to Address Today:

1. **Epidemiology and Pathogenesis**: Spectrum of disease. Congenital defects → pathogenic mechanisms. Are they new or just recently recognized?
2. **Vaccines**: Target populations. Design of clinical trials.
3. **Diagnostics**: Specificity, sensitivity, availability.
4. **Therapeutics**: When and how to use. Role in pregnancy.
5. **Vector control**: Current tools versus novel approaches.